Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 7 of 20 for:    ACTA2

Role of the Peritoneal Microenvironment in the Pathogenesis and Spread of Colorectal Carcinomatosis (MMT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03777943
Recruitment Status : Recruiting
First Posted : December 18, 2018
Last Update Posted : December 18, 2018
Sponsor:
Collaborator:
Belgian Federation Against Cancer
Information provided by (Responsible Party):
GIHeelkunde, University Hospital, Ghent

Brief Summary:
The goal of this project is to investigate the extent and role of mesothelial - mesenchymal transition (MMT) and cancer associated fibroblasts (CAFs) in the pathogenesis of colorectal peritoneal carcinomatosis (PC).

Condition or disease Intervention/treatment Phase
Peritoneal Carcinomatosis Procedure: Sampling peritoneal tissue Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Role of the Peritoneal Microenvironment in the Pathogenesis and Spread of Colorectal Carcinomatosis
Actual Study Start Date : November 1, 2017
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2020

Arm Intervention/treatment
Experimental: Cytoreductive surgery (CRS)
In patients presenting with colorectal peritoneal carcinomatosis, peritoneal tissue will be sampled during surgery at 4 different locations.
Procedure: Sampling peritoneal tissue
Resection specimen will be obtained during CRS from normal peritoneum at a distance, normal peritoneum close to a peritoneal metastasis, miliary peritoneal carcinomatosis, and established peritoneal carcinomatosis.




Primary Outcome Measures :
  1. Immunohistochemistry (IHC) analysis [ Time Frame: Within 6 months after collection of the samples ]
    Extensive IHC analysis will be performed including CD44, integrins, ICAM-1, hyaluronate, and VCAM-1 (adhesion molecules); calretinin, mesothelin, WT1, cytokeratins and E-cadherin (mesothelial markers); α-SMA, FAP and podoplanin (CAF specific markers); PDGF, VEGF and EDGF (angiogenesis related markers)


Secondary Outcome Measures :
  1. Intra-tumoral versus peritoneal vascularity [ Time Frame: Within 6 months after collection of the samples ]
  2. Laser capture microdisssection (LCM) followed by gene expression analysis [ Time Frame: Within 12 months after collection of the samples ]
    Different cell types (mesothelial cells, submesothelial resident fibroblasts, CAFs) will be isolated using LCM, followed by gene expression analysis



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

• Patients presenting with colorectal peritoneal carcinomatosis

Exclusion Criteria:

  • Pregnancy or breast feeding
  • Psychiatric pathology capable of affecting comprehension and judgment faculty
  • HIPEC (hyperthermic intraperitoneal chemotherapy) or PIPAC (pressurized intraperitoneal aerosol chemotherapy) in the past
  • Abdominal radiation treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03777943


Contacts
Layout table for location contacts
Contact: Wim Ceelen +32(0)93326251 wim.ceelen@ugent.be
Contact: Sarah Cosyns +32(0)93321562 sarah.cosyns@ugent.be

Locations
Layout table for location information
Belgium
Ghent University Hospital Recruiting
Ghent, Belgium, 9000
Contact: Wim Ceelen    +32(0)93326251    wim.ceelen@ugent.be   
Sub-Investigator: Sarah Cosyns         
Sponsors and Collaborators
University Ghent
Belgian Federation Against Cancer

Layout table for additonal information
Responsible Party: GIHeelkunde, University Hospital, Ghent
ClinicalTrials.gov Identifier: NCT03777943     History of Changes
Other Study ID Numbers: EC/2017/0784
First Posted: December 18, 2018    Key Record Dates
Last Update Posted: December 18, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Peritoneal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Abdominal Neoplasms
Neoplasms by Site
Digestive System Neoplasms
Digestive System Diseases
Peritoneal Diseases